Ironwood Pharmaceuticals Issues FY26 Guidance, Shares Surge 57.7%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy IRWD?
Source: Benzinga
- Sales Guidance Boost: Ironwood Pharmaceuticals anticipates 2026 US net sales for Linzess to reach between $1.125 billion and $1.175 billion, indicating strong market demand that is expected to drive future revenue growth.
- Revenue Expectations Rise: The company projects total revenue for 2026 to be between $450 million and $475 million, which is likely to enhance investor confidence and attract more capital inflow.
- Strong EBITDA Forecast: Ironwood expects adjusted EBITDA to exceed $300 million in 2026, indicating ongoing improvements in profitability that could elevate its market valuation.
- Significant Stock Surge: Following the announcement, Ironwood's shares surged 57.7% to $5.32, reflecting a positive market reaction to its growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRWD
Wall Street analysts forecast IRWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRWD is 6.23 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.450
Low
5.00
Averages
6.23
High
8.00
Current: 4.450
Low
5.00
Averages
6.23
High
8.00
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
ChowChow Cloud Reports 29% Revenue Growth in H1 2025
- Market Volatility: U.S. stocks traded mixed, with the Dow Jones gaining 0.27% to 48,195.28 points while the NASDAQ fell 0.14% to 23,209.54 points, reflecting uncertainty in the market and divergent investor sentiment.
- Manufacturing PMI Decline: The S&P Global Manufacturing PMI fell from 52.2 to 51.8 in December, indicating a slowdown in manufacturing activity that could impact future economic growth expectations, prompting businesses to adjust strategies to navigate potential market challenges.
- ChowChow Cloud Stock Surge: ChowChow Cloud International Holdings Limited saw its shares rise 29% to $0.78 after reporting year-over-year revenue and net income growth for H1 2025, showcasing the company's strong performance and growth potential in the market.
- Ironwood Pharmaceuticals Guidance Boost: Ironwood Pharmaceuticals, Inc. shares surged 43% to $4.80 following the issuance of FY26 guidance, reflecting the company's confidence in future performance and potentially attracting more investor interest.
See More
Ironwood Pharmaceuticals Shares Surge Following Drug Price Reduction Enhancing Outlook
- Stock Performance: Ironwood Pharmaceuticals' shares surged over 30% in early trading of the new year.
- Sales Outlook: The increase in stock price was driven by a significantly improved sales forecast for 2026.
See More
Ironwood Pharmaceuticals Provides 2026 Guidance, LINZESS Sales Expected to Reach $1.125B to $1.175B
- Sales Forecast Increase: Ironwood anticipates LINZESS sales for fiscal year 2025 to range between $860 million and $890 million, representing a significant increase from $351.4 million in fiscal year 2024, indicating strong market demand and growth potential for the product.
- Total Revenue Outlook: The company expects total revenue for fiscal year 2025 to be between $290 million and $310 million, reflecting the ongoing profitability from its brand collaboration with AbbVie, which will continue to drive financial performance.
- Long-term Market Potential: Ironwood is exploring additional indications for LINZESS, including pediatric use for functional constipation in children aged 6 to 17 years, which will further broaden its market coverage and enhance future revenue streams.
- New Drug Development Progress: Apraglutide is advancing toward a confirmatory Phase 3 trial, which, if successful, could provide a key treatment option for patients with short bowel syndrome, with plans to initiate the trial in the first half of 2026, potentially creating a new revenue stream for the company.
See More
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
ChowChow Cloud Reports 29% Revenue Growth in H1 2025
- Market Volatility: U.S. stocks traded mixed, with the Dow Jones gaining 0.27% to 48,195.28 points while the NASDAQ fell 0.14% to 23,209.54 points, reflecting uncertainty in the market and divergent investor sentiment.
- Manufacturing PMI Decline: The S&P Global Manufacturing PMI fell from 52.2 to 51.8 in December, indicating a slowdown in manufacturing activity that could impact future economic growth expectations, prompting businesses to adjust strategies to navigate potential market challenges.
- ChowChow Cloud Stock Surge: ChowChow Cloud International Holdings Limited saw its shares rise 29% to $0.78 after reporting year-over-year revenue and net income growth for H1 2025, showcasing the company's strong performance and growth potential in the market.
- Ironwood Pharmaceuticals Guidance Boost: Ironwood Pharmaceuticals, Inc. shares surged 43% to $4.80 following the issuance of FY26 guidance, reflecting the company's confidence in future performance and potentially attracting more investor interest.
See More
Ironwood Pharmaceuticals Shares Surge Following Drug Price Reduction Enhancing Outlook
- Stock Performance: Ironwood Pharmaceuticals' shares surged over 30% in early trading of the new year.
- Sales Outlook: The increase in stock price was driven by a significantly improved sales forecast for 2026.
See More
Ironwood Pharmaceuticals Provides 2026 Guidance, LINZESS Sales Expected to Reach $1.125B to $1.175B
- Sales Forecast Increase: Ironwood anticipates LINZESS sales for fiscal year 2025 to range between $860 million and $890 million, representing a significant increase from $351.4 million in fiscal year 2024, indicating strong market demand and growth potential for the product.
- Total Revenue Outlook: The company expects total revenue for fiscal year 2025 to be between $290 million and $310 million, reflecting the ongoing profitability from its brand collaboration with AbbVie, which will continue to drive financial performance.
- Long-term Market Potential: Ironwood is exploring additional indications for LINZESS, including pediatric use for functional constipation in children aged 6 to 17 years, which will further broaden its market coverage and enhance future revenue streams.
- New Drug Development Progress: Apraglutide is advancing toward a confirmatory Phase 3 trial, which, if successful, could provide a key treatment option for patients with short bowel syndrome, with plans to initiate the trial in the first half of 2026, potentially creating a new revenue stream for the company.
See More
